Introduction
Animal models of maternal immune activation (MIA) are widely used as experimental tools to study neurobehavioral and molecular dysfunctions in relation to immunemediated neurodevelopmental disorders and mental illnesses [1 ] . These models have originally been developed with the aim to support human epidemiological studies implicating MIA in the etiology of neuropsychiatric illnesses, including schizophrenia, autism spectrum disorder, depression, and bipolar disorder [1 ] . By virtue of their apparent ease of use, and because they can successfully capture key aspects of various psychiatric disorders, MIA models have made a great impact on researchers concentrating on the developmental and neuroimmunological bases of major mental illnesses [2, 3] . The increasing popularity and success of these models are perhaps best illustrated on the basis of models, in which pregnant animals are treated with poly(I:C) (= polyriboinosinic-polyribocytdilic acid), a synthetic analog of double-stranded RNA (dsRNA) that induces a cytokine-associated viral-like acute phase response [4] . While only a few laboratories applied the poly(I:C)-based MIA model in the early 2000s, the number of scientific reports comprising work with this particular model system increased steadily over the last few years (Figure 1 ; Supplementary Table 1) .
With their increasing use, however, MIA models were also destined to facing increasing variability across different research laboratories. This phenomenon is not exclusively seen in MIA models but appears to be a common feature of various environmental and genetic animal models, irrespective of the research disciplines, in which they fall [5] [6] [7] . While variability can introduce substantial challenges in terms of reproducibility and interpretability of a model [5] [6] [7] , it does not necessarily undermine its validity and utility. Here, we argue that the variability of MIA models can offer several unique opportunities for new (and sometimes unexpected) discoveries, granted that researchers are aware of the potential sources of variability and are open to novel methodological approaches and ways of data analysis.
A-priori and a-posteriori model variability
Since their initial establishment and first appearance in the scientific literature, MIA models have been recognized to be variable in terms of their robustness and outcome specificity. For example, early studies using poly(I:C)-based MIA models in mice showed that the efficacy of this prenatal immune challenge to induce long-term behavioral anomalies critically depends on the dosing of poly(I:C) [8, 9] and the precise timing of its administration [10] . Since then, a number of methodological factors influencing the severity and/or specificity of outcomes in MIA models have been identified (Table 1) [11 ] . Many of these factors, including choice of animal species, genetic background of the animals, and type of immunogen, are inherent characteristics of the experimental design. These factors thus represent planned or intentional sources of variability, which we hereby refer to as 'a-priori variability' (Table 1) . The rationale underlying the introduction of this type of variability is manifold, including (i) the evaluation of species-specific effects of MIA by comparing its consequences in different species such as mice [8] [9] [10] , rats [12, 13 ], spiny mice [14] , pigs [15] , ferrets [16 ] , and non-human primates such as rhesus monkey [17] ; (ii) the identification of subthreshold and suprathreshold effects of MIA through manipulations of immune stimulus intensity and chronicity [8, 9, 18] ; (iii) the examination of possible geneenvironment interactions trough the combination of MIA with discrete genetic manipulations or different strains of wild-type animals [19] ; (iv) the comparison of the effectiveness of different immunogens to alter brain and behavioral development [1 ,2-4,20,21
,22 ]; and (v) the investigation of critical prenatal periods trough manipulations of the maternal immune system at distinct gestational stages [10, 20, 23] .
Substantial variability can also arise from unplanned or unintentional factors. Because these are, to a large extent, only identifiable once the primary readouts (e.g. behavioral data) have been collected and analyzed, we collectively refer to this type of variability as 'a-posteriori variability'. The precise sources underlying 'a-posteriori variability' are often less obvious as compared with those underlying 'apriori variability', and, therefore, their identification requires a systematic investigation. However, with the increasing use of MIA models (Figure 1) , along with the resulting challenges in comparing findings across independent laboratories [11 ] , a number of factors contributing to 'a-posteriori variability' have been identified (Table 1) . These include variability in the immunogenicity of different batches and/or vendor-specific variations of immunogens [24, 25 ], differential susceptibility of isogenic animals obtained from different breeding facilities [26] , and influences of the precise type of caging system [27 ] .
Because of the popularity and utility of MIA models, it is expected that their continuous use will lead to the identification of various other sources of 'a-posteriori variability', which in turn will also help explain factors contributing to within-litter and between-litter variation in multiparous species such as rats and mice [5, 6, 28] . For example, the diurnal light cycle during which animals are tested has a known impact on behavioral functions per se [29] , and, therefore, may also contribute to variability in MIA models. Another likely but yet unexplored source of variability relates to differences in the hygiene status of the animal facility, in which MIA models are conducted. Since the primary experimental manipulation in MIA models is an intervention targeting the immune system, lab-to-lab variations in the hygiene status of breeding and Variability in MIA models Weber-Stadlbauer and Meyer 121 testing facilities can indeed be expected to substantially contribute to 'a-posteriori variability'.
Once identified, some factors contributing to 'a-posteriori variability' can and should be considered as 'a-priori variability'. This is the case, for example, variability associated with the age [30] [31] [32] and sex [33, 34] of the offspring, and for differences in the composition of the maternal microbiome [26] . These sources of variability were initially not predicted by a-priori assumptions, but were recognized as such through the use of longitudinal investigations spanning different ages of MIA-exposed offspring [30] [31] [32] , the comparison of the effects of MIA in male and female offspring [33, 34] , and the examination of the role of microbiome-derived factors in MIA models [26] . As discussed in more detail below, the transfer of newly identified sources of 'a-posteriori variability' into the domains of 'a-priori variability', and their integration into the experimental design of a given MIA model, will readily help to reduce data variance (Figure 2 ).
Ways to counter model variability
A meaningful translation and interpretation of MIA models, like in any other model, require comparability and reproducibility [1
]. The consideration and incorporation of 'a-priori model variability' into experimental designs constitute a pivotal first step to minimize the inconsistency and unpredictability of MIA models. Indeed, some methodological variations causing this type of variability seem obvious (e.g. choice of species, type of immunogen, and dosing) and can easily be integrated into the experimental design. In contrast, researchers may be less aware of the existence of the sources contributing to 'a-posteriori variability' and their impact on the outcomes in MIA models. To illustrate the latter, the effectiveness of a given immunogen to induce brain and behavioral abnormalities may follow differential dose-response curves depending on the animal facility and its prevailing hygiene status [27 ] and may further be affected by variations in the immunogenicity of distinct immunogen batches or vendor-specific variations of the agent used to induce MIA [24, 25 ]. We, therefore, deem it important that researchers working with MIA models establish their own dose-response curves to identify subthreshold and suprathreshold effects in their primary readouts of interest (e.g. behavioral functions), rather than simply relying on doses that were found to be effective in other research laboratories. Ideally, such dose-response studies would involve the concomitant assessment of the immunogen's potency and efficacy, be it through the quantification of certain immune factors such as cytokines [27 ] , or through the analysis of behavioral responses such as sickness behavior [25 ,35] . Once an MIA model of interest has been established to the extent that it produces robust effects, it is advisable to keep the methodological parameters as constant as possible to maximize intra-lab reproducibility. constitution and potency of the chosen immunogen are ascertained for each newly acquired batch of the immunogen.
As discussed in detail elsewhere [36, 37] , accounting for possible between-litter and within-litter variation in multiparous species such as rats and mice is another way to improve reproducibility in MIA models. Related to this, attention should also be directed towards the possible confounds introduced by caging effects. Besides the recently discovered impact of different caging systems per se [27 ], animals that are co-housed in a particular cage usually develop a social relationship whereby one (or a subgroup) predominates over the others [38] . Such social hierarchies are particularly manifest in (but not exclusive to) male mice and are influenced by intra-cage factors such as cage enrichment [39, 40] . Importantly, cage-associated factors can shape individualization, thereby amplifying within-litter variability [38, 40] . While dominant animals explore and commandeer relevant cage microhabitats, subordinates often fail to secure a base for themselves and spend much of their time withdrawing from contact with dominant animals [38] [39] [40] . These hierarchy-related cage factors may change the levels of perceived stress in subordinate animals, which in turn may be a central driving force for within-litter individualization. Whether, or to what extent, within-litter individualization resulting from intra-cage factors contributes to variability in MIA models remains unknown. This question clearly warrants examination, especially given the previous findings showing that MIA can interact with stress during peripubertal maturation to shape the nature and/or severity of adult behavioral and neurochemical abnormalities [41] .
Even if, and especially if, some sources of variability remain indefinable and difficult to approach, it is pivotal for the field to report the methodological details of the chosen MIA model [11 ] . Adhering to recently established reporting guidelines [11 ] will readily improve transparency and comparability of MIA models across laboratories. In addition, well-organized community efforts, coupled with improved data and metadata sharing, will facilitate the identification of novel sources of 'a-posteriori variability' in MIA models and will have a key role in promoting satisfactory ways to approach them.
Opportunities of model variability
Despite the multiple types andsourcesof variability (Table 1) , a number of phenotypes in MIA models are reproducible within and between different research laboratories, and even across different species [4,9,11 ,17] . While reproducibility against the background of methodological variability may appear paradoxical, systematic variation in experimental conditions (i.e. heterogenization) can actually maximize rather than minimize reproducibility [5, 6] . Indeed, experimental Schematic illustration summarizing the influence of 'a-priori variability' and 'a-posteriori variability' on data variance in maternal immune activation models. Planned or intended sources of variability are referred to as 'a-priori variability', whereas unplanned or unintended sources are referred to as 'a-posteriori variability'. 'A-priori variability' (e.g. choice of animal species or strain, choice of immunogen, and intensity or chronicity of immune activation) is an integral part of the experimental design and leads to expected data variance in maternal immune activation model. In contrast, the precise sources of 'a-posteriori variability' are only identifiable once the primary readouts (e.g. behavioral data) have been collected and analyzed, and these are often less obvious as compared with the sources of 'a-priori variability'. Once identified, some factors contributing to 'a-posteriori variability' can and should be considered as 'a-priori variability'. The transfer of newly identified sources of 'a-posteriori variability' into the domains of 'a-priori variability', and their integration into the experimental design of a given maternal immune activation model, will readily help to reduce data variance. As outlined in Table 1 , both types of variability offer various opportunities for new discoveries in maternal immune activation models.
standardization can generate spurious results by increasing test sensitivity at the expense of external validity [5, 6] . It needs to be determined; however, whether the reproducibility and robustness of some phenotypes in MIA models [4,9,11 ,17] are driven by experimental heterogenization or not.
Variability and data variance can also offer some unique opportunities in MIA models. First of all, the multitude of immunogens that are currently used in MIA models (Table 1) allows researchers to explore possible convergence between the pathological effects induced by different immune-activating agents and their downstream signaling pathways. Making use of this type of 'a-priori variability' has already led to the identification of both common and dissimilar effects of MIA when induced by distinct immunogens [4, 9, 20, 21 ,22
,24]. Likewise, the use of cross-species approaches in MIA models helps to minimizing the potential for overinterpreting or oversimplifying the findings obtained in a certain animal species or strain [1 ,17] . Although the majority of MIA models have been developed in rodent species, mostly in rats and mice (Figure 1) , some have been extended to species that are evolutionarily and ethologically closer to humans, including rhesus monkeys [17] . The latter species exhibit greater similarity to humans in terms of genetics, immunology, neurobiology, and behavior, and compared with rodents, it is also more comparable to humans in terms of placental physiology, gestational timelines, prenatal and postnatal brain development, and cortical architecture [17, 42, 43] . Thus, the inclusion of species that are genetically more similar to humans, such as the rhesus monkey, can aid in interpreting the outputs of rodent MIA models in terms of what they might mean for pathological symptoms in humans, thereby enhancing the cross-species transfer of information and translatability to the clinical condition in humans.
Compared with the notable benefits of 'a-priory variability', the possible opportunities offered by 'a-posteriori variability' in MIA models appear less obvious. Even within a particular type of MIA model, the variability of immunological, behavioral, and molecular data can be quite large [18, 44, 45] , which in turn may minimize or even nullify differences between groups when treated as experimental entities. As discussed above, such variability can readily stem from inherent or experimentally induced litter-to-litter variation and, in the case of multiparous species, from within-litter phenotypic variation. In our opinion, between-litter and within-litter variability can both offer ample opportunities for new discoveries. For example, between-litter variation can be used to examine why some pregnancies are more susceptible to MIA than others. To this end, a recent prospective analysis of the effects of poly(I:C)-induced MIA on maternal cytokines during pregnancy and behavior in rat offspring suggests that the degree of maternal CXCL1 secretion, along with post-acute changes in maternal temperature and body weight changes and alterations in neonatal pup mass, may contribute to between-litter variability and predict, to some extent, the degree of behavioral and cognitive deficits in adult offspring [13 ] .
Within-litter variability can be used to identify factors that contribute to phenotypic susceptibility and resilience in MIA-exposed offspring. Plausible candidate factors contributing to within-litter variability are (i) uteroplacental positioning causing varying immune responses and hormonal exposures during fetal brain development [46, 47] ; (ii) individualization of littermates resulting from the establishment of post-weaning social hierarchies [38] [39] [40] ; and (iii) stochastic epigenetic variability and subsequent variation in gene transcription during brain development and maturation [48] .
Notably, phenotypic variability is also a common characteristic of multi-factorial and multi-symptomatic mental illnesses such as schizophrenia and autism spectrum disorder [49] [50] [51] . Therefore, the existence of variability in animal models can also be used to identify the sources of phenotypic variability in human pathological conditions. For example, unpublished data from our laboratory suggest that only a subgroup (40-50%) of MIA-exposed offspring show persistent elevations in cytokine-associated inflammatory profiles in the adult brain. The extent to which MIA offspring can be stratified into high and low inflammatory subgroups is markedly similar to the stratification of schizophrenia cases into high and low inflammatory biotypes [52] , suggesting that MIA may represent one of the contributing factors underlying the variable neuroimmune changes in the brains of people with schizophrenia. Notably, such subgroup analyses in MIA models can further be used to determine whether a high immune status correlates with, or even causes, more pronounced behavioral changes and cognitive deficits in offspring exposed to MIA.
Taking maximal advantage of variability in MIA models requires researchers to open up to new (or modified) methodological approaches and ways of data analysis. For example, identifying susceptible and resilient mothers and/or offspring, and unraveling the mechanisms underlying this segregation, would necessitate the use of relatively large numbers of litters and whole-litter testing approaches. Furthermore, the identification of pathological entities that go beyond predefined treatment groups requires advanced statistical methods, such as clustering approaches, principal component analyses, and perhaps even machine learning. The latter offers a powerful and unbiased approach in many areas of behavioral sciences [53] , which often entail diverse, complex, and high-dimensional data sets exhibiting nonlinear dependencies and unknown interactions across multiple variables. Like in other research domains [53] , the datasets obtained in MIA models may fail to conform to the assumptions of many classical statistical methods, and, therefore, machine learning might offer an additional approach to extract new knowledge from these data.
Challenges and opportunities of variability beyond MIA models
For the same reasons discussed above in the context of MIA models, variability and data variance can be challenging and inspiring at the same time in any domain of psychoneuroimmunological research. For example, it was noticed long ago that exposure to psychological stressors can induce changes in autonomic, endocrine, and immune functions, yet all of which show large interindividual differences [54] . While the heterogeneity in the responses to psychological stressors may minimize simple group effects (e.g. stressed versus non-stressed), it offers researchers to identify subentities or subgroups with distinct 'biotypes' or response patterns. To illustrate the latter, Cacioppo et al. [54] found that individuals characterized by high cardiac sympathetic reactivity to brief psychological stressors showed higher stress-related changes in adrenocorticotropic hormone (ACTH) and cortisol plasma as compared to those individuals characterized by low cardiac sympathetic reactivity. Subsequent studies further revealed that individuals who showed the greatest stress-induced changes in hypothalamus-pituitary adrenal (HPA) axis activation also exhibited the greatest attenuation of cellular immune responses [55] . Such studies were pivotal for the field as they paved the way for comprehensive and continuous research into stress resilience and vulnerability [56, 57] . They also highlighted that stratifying nosologically defined cohorts of patients based on distinct 'biotypes' may have the potential for more efficacious therapeutic interventions. The seminal study by Raison et al. [58] is an illustrative example for the latter, demonstrating that antagonism of tumor necrosis factor (TNF) via treatment with infliximab does not have generalized efficacy in treatment-resistant depression but improves depressive symptoms in patients with high baseline inflammatory biomarkers.
Research investigating the role of microbiota in health and disease is another research domain where variability and data variance are common and challenging [59, 60] . While differences in the composition of the maternal microbiome can influence the outcomes of MIA models (see above), the effects induced by interventions targeting primarily the microbiota can vary considerably, making it difficult to replicate findings [59] [60] [61] . Moreover, the interindividual variability in microbiota can be substantial even in genetically identical animals [59, 60] , which in turn may undermine the reproducibility of genetic animal models used in psychoneuroimmunological research and elsewhere. Despite these challenges, however, interindividual differences in the composition of the microbiome may offer a fruitful avenue for personalized medicine, in which the microbiome can be harnessed as a central precision medicine target [62] .
Conclusions
The design, implementation, and interpretation of MIA models require adequate time considering planned or intended ('a-priori variability') and unplanned or unintended ('a-posteriori variability') sources of variability and developing appropriate strategies to handle them. While every research group may have its own strategy to this aim, it is pivotal for the field to report the methodological details of the chosen MIA model in order to enhance transparency and comparability of MIA models across laboratories and to maximize translatability to human conditions. The growing understanding of the potential sources of variability (Table 1) now offers an increasing number of ways for minimizing variability in MIA models. We believe, however, that variability is not necessarily an undermining characteristic of MIA models, nor is it an insurmountable obstacle for new discoveries and developments in this field. In fact, variability in MIA models provides unique opportunities to identify mechanisms determining susceptibility and resilience in relation to immune-mediated neurodevelopmental disorders and mental illnesses. Granted that researchers are aware of the potential sources of variability and are open to novel methodological approaches and ways of data analysis, variability, and data variance can be similarly inspiring for any domain of psychoneuroimmunological research.
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In this study, the authors compared poly(I:C)-based maternal immune activation (MIA) models in two commonly used animal housing systems, namely the open cage (OC) and individually ventilated cage (IVC) systems. They found that maternal poly(I:C) administration on gestation day (GD) 9 caused a dose-dependent increase in spontaneous abortion in IVCs but not in OCs, whereas MIA in IVC systems during a later gestational time-point (GD 12) did not affect pregnancy outcomes. Moreover, the precise type of caging system markedly affected maternal cytokines and chemokines at basal states and in response to poly(I:C) and further influenced the maternal levels of the stress hormone, corticosterone. The efficacy of MIA to induce deficits in working memory, social interaction, and sensorimotor gating in the adult offspring was found to be influenced by the different housing conditions, the dosing of poly(I:C), and the precise prenatal timing. Taken together, this study identifies the basic type of caging system as a novel factor that can confound the outcomes of MIA in mice. These findings, thus, urge the need to consider and report the kind of laboratory housing systems used to implement MIA models.
